Compare Gilead Sciences, Inc. (GILD) vs iShares Gold Trust (IAU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs iShares Gold Trust — how do they compare? Gilead Sciences, Inc. trades at $151.17 (market cap $182.40B), while iShares Gold Trust trades at $78.87 (market cap $61.51B). The key difference: Gilead Sciences, Inc. is far larger — about 3× iShares Gold Trust's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while iShares Gold Trust pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and iShares Gold Trust for 49 Days on average.
| GILD | IAU | |
|---|---|---|
Market Cap | $182.40B | $61.51B |
Volume | 4,469,821 | 3,206,729 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $155.80 | $101.57 |
52-Week Low | $116.74 | $74.21 |
Typical Hold Time | 111 Days | 49 Days |
Enterprise Value | $205.46B | — |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $151.17, up 2.94% recently, with strong technical momentum and bullish moving averages. The company shows robust revenue growth to $29.44B in 2025 and beat earnings estimates in three consecutive quarters, though net income margin turned negative at -10.64% for 2026. Recent developments include expanded HIV drug access in Latin America via a PAHO partnership, positioning Gilead for growth in its core franchises.
Gilead presents a mixed outlook with solid operational cash flow and analyst bullishness (65.5% buy ratings) offset by profitability concerns and high debt levels. The stock's current price aligns with the consensus target of $151.57, suggesting limited near-term upside. Key risks include execution in oncology pipeline expansion and reliance on HIV treatment revenues amid competitive pressures.
IAU stock trades at $78.87, up 2.35% today, but faces strong technical bearish signals with 13 of 13 moving averages indicating sell signals. The stock shows neutral momentum oscillators with RSI levels at 40.80 (6-day) and 31.31 (12-day) suggesting potential oversold conditions. Recent market sentiment reflects gold's sensitivity to interest rate expectations and Treasury yield movements.
Investment outlook remains cautious with technical indicators predominantly bearish and gold prices facing headwinds from rising yields. The stock's proximity to key support at $76-77 creates a critical level to watch, while Federal Reserve policy decisions on interest rates will likely drive near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About iShares Gold Trust
IAU is a physically backed ETF that seeks to reflect the performance of the price of gold. It provides a convenient and liquid way for investors to include gold in their portfolios as a potential hedge.
Read more on IAU →
